|Bid||14.81 x 1400|
|Ask||14.83 x 1800|
|Day's Range||14.66 - 15.27|
|52 Week Range||8.28 - 25.02|
|Beta (3Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.14|
10 is a majestic number. Used to bestow a quality of unmatched excellence, be it as a score in a gymnastics routine, or as a number on the back of a sportsman/woman’s shirt, indicating leadership and guru-like status.TipRanks makes good use of the aspirational number too. The Smart Score tool combines 8 key metrics that can indicate a stock’s long-term growth potential. The data is analyzed, and the stock is given a score accordingly. The highest score, naturally, is a “Perfect 10”.Setting out on our quest for perfection, with the Smart Score’s assistance, we homed in on 3 Perfect 10 Stocks with plenty of room for growth ahead. Let’s take a look.Yeti Holdings (YETI)Unicorn brands are a rare sight; hence they’re called - you guessed it - unicorn brands. The title refers to a privately held company that reaches a value of $1 billion. One such brand making quite a splash since going public is Yeti Holdings.The outdoor product manufacturer held its IPO in October 2018 and has mostly been on a cool upward trend ever since. It has made excellent progress in building its brand identity, seducing lovers of the outdoor lifestyle with its varied line of products. As a result, it now boasts 1.3 million followers on Instagram. Following previous strong quarters, 3Q continued the trend. Sales came in at $229M beating the $222M estimate, alongside increasing sales growth. Yeti delivered on EPS too - at $0.30 it beat the Street’s estimate of $0.26.Looking ahead, Jefferies’ 4-star analyst Randal Konik thinks the growth is set to continue, noting, “YETI is a brand that consumers (Pros/ Joes) love & also see as a gifting destination.” He adds, “We see significant opportunity for YETI to expand its TAM as it broadens its exposure to non-heritage markets in the US and international over the long-term. With continuous innovation in new and existing product categories, and a quickly growing margin-enhancing DTC channel, we believe top-line and margin opportunities are significant.” On the back of his analysis, Konik reiterated a Buy rating on Yeti, with a price target of $47.00, providing potential upside of almost 60%. (To watch Konik’s track record, click here)Another analyst singing YETI’s praises is Piper Jaffrey’s Peter Keith, who said, “Business momentum remains strong and we see upside to implied Q4 guidance. Importantly, we believe YETI is demonstrating longer-term growth potential, considering success with new product launches, steady/consistent gross margin expansion, intriguing store expansion opportunity both w/ Wholesale and DTC, and engaging marketing.” Like Konik, Keith reiterated a Buy on the stock, with a price target of $39.00. (To watch Keith’s track record, click here)The analysts’ positive sentiment is shared by the Street, as Yeti currently ranks as a Strong Buy. The cooler manufacturer has a consensus of 7 Buys and 1 Hold with an average price target of $40.50. This implies handsome potential upside of over 37% from its current price of $29.41. (See Yeti stock analysis on TipRanks)CryoPort (CYRX)With a motto of “Science. Logistics. Certainty.” CryoPort, which provides cold chain logistics solutions to the life sciences industry, presents itself boldly.In layman’s terms, it is a frozen shipping container company moving biological specimens around the world in sub-zero temperatures. Its clients include biopharmaceutical, IVF and surrogacy as well as animal health organizations across the globe.The company recently posted strong 3Q19 results, with revenue up 81% year-over-year, and positive adj. EBITDA for the second consecutive quarter. Among the highlights in the report were increased market share in the regenerative medicine clinical trial sector and a strategic partnership with Lonza. Lonza provides product development services to the pharmaceutical and biologic industries and is considered one of the largest players in the field. Needham’s 4-star analyst Stephen Unger thinks the partnership is good news for CryoPort, noting, “The goal of the partnership is to provide customers developing cell and gene therapies with a fully integrated solution for outsourced manufacturing and cold-chain logistics, which we see increasing customer visibility of CYRX's best-in-class logistics solutions earlier in the therapy development process.” Following the quarterly report and positive developments, Unger maintained his Buy rating on CYRX. His price target is $24.00. (To watch Unger’s track record, click here)B.Riley FBR’s Andrew D'Silva is also impressed with the partnership. The analyst said, “We believe Lonza has positioned itself as one of the cell and gene therapy industry's leading contract development and manufacturing organizations (CDMOs). As a result, we believe CYRX being selected as Lonza's preferred partner is another substantial validation for the company and should help further increase CYRX's logistics volumes.”To this end, D’Silva reiterated his Buy rating on CYRX stock, along with a price target of $26.00, providing potential upside of 70%. (To watch D’Silva’s track record, click here) Not many analysts have presently weighed in on the small cap’s potential for the year ahead. With a consensus of 2 Buys, CYRX currently ranks as a Moderate Buy. That being said, the average price target is $25.00, implying nice upside of almost 64% from its current price of $15.56. (See Cryoport stock analysis on TipRanks)Sonos (SONO)Speakers act louder than words, so the phrase goes. Well, not quite, but it does lead us nicely to our final choice.Consumer electronics company Sonos is mostly known for its smart speakers. Apart from the excellent sound quality, Sonos’ Sonoset system creates a custom Wi-Fi network, eliminating the need for old fashioned wires and allowing for music to be played simultaneously in different rooms. This is great for household systems, and earlier this year Sonos partnered with furniture giant Ikea on a new line of products, an alliance RBC Capital’s Robert Muller thinks has the potential to drive new customer adoption. The analyst said, “We believe the true value of Sonos lies in the family ecosystem whereby additional speakers complement one another. Once exposed to Sonos, we expect new customers to quickly envision the benefits of additional speakers throughout their homes. If SONO is able to expand the number of homes it's in (currently in ~8MM worldwide with nearly 4MM in the US), we should see a wave of secondary purchases.”Emphasizing this thesis, Muller says almost 4 out of 10 new purchases are from existing Sonos customers. Furthermore, the analyst also views SONO as a potential acquisition target for one of the tech giants, adding, “We do not believe current valuation adequately captures acquisition potential, expansion opportunities, or current baseline growth”. Following his analysis, Muller initiated coverage, along with a price target of $18.00. (To watch Muller’s track record, click here). A consensus rating of 3 Buys and 1 Hold means the Street is ready to turn the volume up on Sonos, rating the speaker manufacturer as a Strong Buy. The average price target is $18.25, providing upside of 24% from its current price of $14.70. (See Sonos stock analysis on TipRanks)
Cryoport now supports 425 clinical trials in Regenerative Medicine market Revenue from commercial therapies increased 368% over same quarter last year and 39% sequentially IRVINE, Calif. , Nov. 7, 2019 ...
- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis - Partnership incorporates Cryoport's Cryoportal® Logistics Management Platform, SmartPak ...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
IRVINE, Calif., Oct. 31, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2019 on Thursday, November 7, 2019 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2019 in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, November 7, 2019. Cryoport management will host a conference call at 5:00 pm ET on November 7, 2019.
While Cryoport, Inc. (NASDAQ:CYRX) shareholders are probably generally happy, the stock hasn't had particularly good...
IRVINE, Calif. , Oct. 9, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, announce a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies. This agreement with Cryoport will contribute to this, alongside other solutions including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals. “Control and monitoring are critical because a simple temperature variation can jeopardize these cells and, ultimately, the product we supply to patients.
IRVINE, Calif., Sept. 18, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, today announced the launch of its Advanced Therapy Shipper™ product line for the regenerative medicine market. The Advanced Therapy Shipper™ guarantees each shipper has been used only for human use and provide complete traceability of all equipment, components and commodities. The result is unmatched verification information and unmatched supply chain support for biopharma companies researching and commercializing cell and gene therapies.
Collaboration between industry-leading supply chain orchestration (SCO) platform and the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities will bring the capabilities to support hundreds of advanced therapy clinical centers, clinical trials and commercially approved products worldwide. SAN FRANCISCO and IRVINE, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Vineti, Inc., and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) announced a commercial partnership designed to extend end-to-end delivery of cell therapies and gene therapies to a growing number of patients as the industry continues to scale. Pairing Vineti’s supply chain orchestration (SCO) platform with Cryoport’s integrated temperature-controlled capabilities and near real-time monitoring will provide an end-to-end solution for advanced therapies, supporting the assurance of improved drug product quality and patient safety. Vineti and Cryoport together seek to leverage both of their commercial and clinical phase experiences and insights from serving biopharma customers.
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
Cryoport now supports 413 clinical trials in regenerative medicine Cryoport supports the commercial launch of bluebird bio's Zynteglo™ in Europe IRVINE, Calif. , Aug. 8, 2019 /PRNewswire/ -- Cryoport, ...
Every investor in Cryoport, Inc. (NASDAQ:CYRX) should be aware of the most powerful shareholder groups. Generally...
In addition to the earnings release, a document titled "Cryoport Second Quarter 2019 in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, August 8. Cryoport management will host a conference call at 5:00 pm ET on August 8, 2019.
IRVINE, Calif., July 11, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) and EVERSANA™ have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.
If you're interested in Cryoport, Inc. (NASDAQ:CYRX), then you might want to consider its beta (a measure of share...
IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) ("Cryoport" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of 3,750,000 newly issued shares of common stock at a price of $17.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock. The net proceeds to the Company from the offering of the shares are expected to be approximately $59.8 million after deducting underwriting discounts and commissions and estimated offering expenses, and assuming no exercise of the underwriters' option to purchase additional shares.
IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) ("Cryoport" or the "Company") today announced that it intends to offer shares of common stock in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC"). Cryoport also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering are to be sold by Cryoport.
IRVINE, Calif., June 5, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) (or the "Company"), the world's leading temperature-controlled supply chain company dedicated to the life sciences industry, today announced its Chief Executive Officer, Jerrell Shelton, and other members of the management team, will ring the Nasdaq closing bell on Monday, June 10, 2019. Jerrell Shelton will be interviewed live on the "The Watch List" on the TD Ameritrade Network, on Monday, June 10, 2019 at 1:00PM Eastern Time. The Cryoport closing bell ceremony will be broadcast live starting at 3:45pm Eastern Time from the Nasdaq MarketSite Tower in New York City.
IRVINE, Calif., May 16, 2019 /PRNewswire/ -- CalAmp (CAMP), an advanced technology solutions pioneer transforming the global connected economy, today announced a strategic collaboration with Cryoport (CYRX) (Nasdaq:CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, to develop a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments. This research and development collaboration is aimed at enhancing the protection and preservation of critical life science shipments, which demonstrates CalAmp's continued momentum in the supply chain visibility market and Cryoport's commitment to providing the most advanced best-in-class, data-driven solutions to its biopharmaceutical client base.